BACKGROUND: The relationship between prognosis of advanced pancreatic cancer and exocrine secretion impairment is unknown. AIM: To investigate a possible correlation between faecal elastase-1 value and survival in advanced pancreatic cancer. METHODS: 194 patients with advanced pancreatic cancer were prospectively enrolled between 2007 and 2009 and underwent faecal elastase-1 measurement. Exocrine pancreatic secretion was defined as "moderately reduced" (faecal elastase-1: 100-200 μg/g), "severely reduced" (faecal elastase-1<100 and >20 μg/g) and "extremely reduced" (faecal elastase-1≤20 μg/g). RESULTS: Median faecal elastase-1 was 204 μg/g (interquartile range 19; 489). Overall, 48 patients (25%) had an extremely reduced exocrine pancreatic secretion, 28 (14%) a severely reduced exocrine pancreatic secretion and 21 (11%) a moderately reduced exocrine pancreatic secretion. Patients with extremely reduced exocrine pancreatic secretion had higher rates of pancreatic head localizations (P<0.01) and of jaundice (P<0.01). Median overall survival was 10.5 months. Patients with faecal elastase-1≤20 μg/g had a worse prognosis (median survival: 7 versus 11 months, P=0.031). Presence of metastases (Hazard ratio 1.81, P<0.0001), haemoglobin ≤12 g/L (Hazard ratio 2.12, P=0.001), albumin ≤40 g/L (Hazard ratio 1.64, P=0.010) and FE-1≤20 μg/g (Hazard ratio 1.59 P=0.023) resulted as independent predictors of survival in advanced pancreatic cancer patients. CONCLUSIONS: A low value of faecal elastase-1 is strongly correlated with a poor survival in advanced pancreatic cancer.
BACKGROUND: The relationship between prognosis of advanced pancreatic cancer and exocrine secretion impairment is unknown. AIM: To investigate a possible correlation between faecal elastase-1 value and survival in advanced pancreatic cancer. METHODS: 194 patients with advanced pancreatic cancer were prospectively enrolled between 2007 and 2009 and underwent faecal elastase-1 measurement. Exocrine pancreatic secretion was defined as "moderately reduced" (faecal elastase-1: 100-200 μg/g), "severely reduced" (faecal elastase-1<100 and >20 μg/g) and "extremely reduced" (faecal elastase-1≤20 μg/g). RESULTS: Median faecal elastase-1 was 204 μg/g (interquartile range 19; 489). Overall, 48 patients (25%) had an extremely reduced exocrine pancreatic secretion, 28 (14%) a severely reduced exocrine pancreatic secretion and 21 (11%) a moderately reduced exocrine pancreatic secretion. Patients with extremely reduced exocrine pancreatic secretion had higher rates of pancreatic head localizations (P<0.01) and of jaundice (P<0.01). Median overall survival was 10.5 months. Patients with faecal elastase-1≤20 μg/g had a worse prognosis (median survival: 7 versus 11 months, P=0.031). Presence of metastases (Hazard ratio 1.81, P<0.0001), haemoglobin ≤12 g/L (Hazard ratio 2.12, P=0.001), albumin ≤40 g/L (Hazard ratio 1.64, P=0.010) and FE-1≤20 μg/g (Hazard ratio 1.59 P=0.023) resulted as independent predictors of survival in advanced pancreatic cancerpatients. CONCLUSIONS: A low value of faecal elastase-1 is strongly correlated with a poor survival in advanced pancreatic cancer.
Authors: Daniel de la Iglesia; Bartu Avci; Mariia Kiriukova; Nikola Panic; Maryana Bozhychko; Vasile Sandru; Enrique de-Madaria; Gabriele Capurso Journal: United European Gastroenterol J Date: 2020-07-06 Impact factor: 4.623
Authors: Donghui Li; Yixiang Mao; Ping Chang; Chang Liu; Manal M Hassan; Saiching J Yeung; James L Abbruzzese Journal: Am J Cancer Res Date: 2015-09-15 Impact factor: 6.166
Authors: Nicholas Zdenkowski; George Radvan; Leanna Pugliese; Julie Charlton; Christopher Oldmeadow; Allison Fraser; Antonino Bonaventura Journal: Support Care Cancer Date: 2017-02-04 Impact factor: 3.603
Authors: Igor E Khatkov; Igor V Maev; Sayyar R Abdulkhalov; Sergey A Alekseenko; Ruslan B Allikhanov; Igor G Bakulin; Natalia V Bakulina; Andrey U Baranovskiy; Ekaterina V Beloborodova; Elena A Belousova; Sergey E Voskanyan; Lyudmila V Vinokurova; Vladimir B Grinevich; Vladimir V Darvin; Elena A Dubtsova; Tatiana G Dyuzheva; Vyacheslav I Egorov; Mikhail G Efanov; Roman E Izrailov; Vyacheslav L Korobka; Bogdan N Kotiv; Nikolay Yu Kokhanenko; Yury A Kucheryavy; Maria A Livzan; Vladimir K Lyadov; Karine A Nikolskaya; Marina F Osipenko; Victor D Pasechnikov; Ekaterina Yu Plotnikova; Oleg A Sablin; Vladimir I Simanenkov; Victor V Tsvirkun; Vladislav V Tsukanov; Alexey V Shabunin; Dmitry S Bordin; Professional Medical Society Pancreatic Club Russia Journal: Turk J Gastroenterol Date: 2021-03 Impact factor: 1.852
Authors: Mary E Phillips; Andrew D Hopper; John S Leeds; Keith J Roberts; Laura McGeeney; Sinead N Duggan; Rajesh Kumar Journal: BMJ Open Gastroenterol Date: 2021-06